Haleon plc/£HLN
1D1W1MYTD1Y5YMAX
Capital at risk
About Haleon plc
Haleon plc is a consumer healthcare company that focuses on the development, manufacturing, and distribution of health products. The company operates in the healthcare industry, specifically targeting wellness and over-the-counter products. Haleon's portfolio includes well-known brands such as Sensodyne, Advil, and Centrum, which are aimed at providing solutions for oral health, pain relief, and dietary supplementation. Headquartered in the United Kingdom, the company maintains a global presence with a significant geographic footprint in numerous markets. Haleon's strategic positioning lies in its focus on scientifically backed consumer health products and a robust brand portfolio, which supports its competitive presence in the healthcare sector.
- Ticker
- £HLN
- Sector
- Health
- Primary listing
- LSE
- Employees
- 24,535
- Headquarters
- Weybridge, United Kingdom
- Website
- www.haleon.com
Haleon plc Metrics
BasicAdvanced
£29B
18.43
£0.18
0.25
£0.07
2.13%
Price and volume
Market cap
£29B
Beta
0.25
52-week high
£4.16
52-week low
£3.18
Average daily volume
20M
Dividend rate
£0.07
Financial strength
Current ratio
0.687
Quick ratio
0.508
Long term debt to equity
38.26
Total debt to equity
50.195
Dividend payout ratio (TTM)
39.00%
Interest coverage (TTM)
8.08%
Profitability
EBITDA (TTM)
2,848
Gross margin (TTM)
65.57%
Net profit margin (TTM)
14.55%
Operating margin (TTM)
23.48%
Effective tax rate (TTM)
23.25%
Revenue per employee (TTM)
£450,000
Management effectiveness
Return on assets (TTM)
5.08%
Return on equity (TTM)
10.09%
Valuation
Price to earnings (TTM)
18.435
Price to revenue (TTM)
2.667
Price to book
1.81
Price to tangible book (TTM)
-3.17
Price to free cash flow (TTM)
13.354
Free cash flow yield (TTM)
7.49%
Free cash flow per share (TTM)
0.25
Dividend yield (TTM)
2.13%
Growth
Revenue change (TTM)
1.21%
Earnings per share change (TTM)
8.46%
3-year revenue growth (CAGR)
-0.75%
3-year earnings per share growth (CAGR)
10.83%
3-year dividend per share growth (CAGR)
20.23%
What the Analysts think about Haleon plc
Analyst ratings (Buy, Hold, Sell) for Haleon plc stock.
Analyst projections of the future price of Haleon plc stock.
Bulls say / Bears say
Q2 organic revenue growth accelerated to 3.1%, balanced between price (+1.7%) and volume/mix (+1.4%), driven by strong momentum in North America, oral health innovation, and emerging markets (Haleon).
Adjusted operating profit grew 8.2% at constant currency in H1, underpinned by a 140 basis point gross margin expansion due to productivity improvements and cost control (Haleon).
Free cash flow rose to £769 million in H1, up £35 million year-on-year, funding £457 million of share buybacks and a 9% interim dividend increase, demonstrating strong cash generation and disciplined capital allocation (Haleon).
H1 reported operating profit fell 2.6% to £1,172 million, with operating margin contracting by 110 basis points, reflecting restructuring costs and ongoing margin pressure in challenging markets (Haleon).
Sluggish European demand and weak respiratory sales in H1 raised doubts about Haleon’s ability to meet its 4–6% medium-term organic growth target, implying a heavier reliance on a stronger second half to hit guidance (Reuters).
Rising freight surcharges linked to the Iran conflict are expected to increase, potentially eroding margins despite fixed-price contracts and hedging arrangements, adding cost volatility risk (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Haleon plc Financial Performance
Revenues and expenses
Haleon plc Earnings Performance
Company profitability
Upcoming events
Funds containing Haleon plc
AllEURGBPUSD
Fund name | Fund size | £HLN weighting |
|---|---|---|
iShares MSCI Europe Health Care Sector€ESIH | €863M | 2.39% |
iShares MSCI Europe Health Care Sector£ESIH | £741M | 2.39% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 2.19% |
iShares Core FTSE 100£CUKX | £3.2B | 1.30% |
Vanguard FTSE 100£VUKE | £4.8B | 1.24% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.